NSE: BIOCON · 14 October 2026
- Biocon Limited shares are trading higher by 0.82% at ₹349.20, moving near the lower end of the day's range between ₹347.35 and ₹350.60.
- Biocon announced that its Pertuzumab biosimilar became the first such product to secure an EMA CHMP approval recommendation under a new tailored clinical approach. The positive scientific opinion marks a key regulatory milestone for the company's biosimilar pipeline in European markets. The update was formally communicated through an NSE filing on September 21, 2026.
- Trading volume was 0.06 times the 20-day average daily volume.
Why is Biocon Limited. share price rising on 14 October 2026?
Biocon Limited shares are trading higher by 0.82% at ₹349.20, moving near the lower end of the day's range between ₹347.35 and ₹350.60.
The broader market showed positive momentum as the Nifty advanced 0.13%, though sector sentiment remained weak with the Nifty Pharma index declining by 1.13%. Despite the broader weakness in pharmaceutical peers, Biocon managed to eke out modest gains, attempting to stabilise after a pullback that saw the stock drop 5.39% over the past 5 trading days and 10.61% over the past 20 trading days.
Recent fundamental developments for the company include a 10-year supply contract for Pertuzumab secured in Brazil on September 08, 2026, alongside an EMA CHMP approval recommendation for the same biosimilar under a tailored clinical approach on September 21, 2026. While these operational updates improve long-term visibility, there is no single same-day catalyst linking these disclosures directly to today's minor price tick.
1.70 lakh shares traded by 14 October 2026 · 09:45 AM IST. This compares with a 20-day average daily volume of 29.53 lakh shares (0.06 times). The five-day average daily volume was 31.45 lakh shares. Separately, the NSE report for 13 October 2026 showed 12.52 lakh shares delivered, representing 53.15% of that day’s traded volume. The same report recorded 31,288 trades.
With no new same-day fundamental catalyst or exchange filing reported, today's 0.82% gain appears to be a modest technical consolidation following a sharp 5-day decline of 5.39% and a 20-day drop of 10.61%. Volume remains exceptionally light at a fraction of normal averages.
Latest Company Developments
Biocon announced that its Pertuzumab biosimilar became the first such product to secure an EMA CHMP approval recommendation under a new tailored clinical approach. The positive scientific opinion marks a key regulatory milestone for the company's biosimilar pipeline in European markets. The update was formally communicated through an NSE filing on September 21, 2026.
This regulatory milestone strengthens the company's competitive positioning in international biosimilar markets, though its financial contribution depends on commercial launch timelines.
The company announced a long-term supply agreement on September 08, 2026, securing a 10-year contract for Pertuzumab in Brazil. The deal establishes a firm commercial footprint in Latin America for this oncology product. Execution details and shipment schedules were outlined in the official regulatory disclosure.
A material 10-year supply agreement improves long-term revenue visibility and capacity utilisation, subject to execution timelines and project margins.
a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Communication regarding remittance of final dividend for the FY 2025-26.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 15.47% on 30 June 2026. This compares with 15.49% on 29 June 2026, a change of -0.02 percentage points.
The filing reported 39 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and commercial rollout timelines for the Pertuzumab biosimilar following the EMA CHMP recommendation and Brazil supply contract.
- Delivery volume trends and whether cash participation picks up from the current 53.15% level.
- Sector performance of Nifty Pharma to see if broader pharmaceutical weakness persists or reverses.
- Stock price reaction relative to the recent block deal pricing level of ₹385 seen in September.
Other Dated Coverage
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
Biocon announced that its Pertuzumab biosimilar became the first such product to secure an EMA CHMP approval recommendation under a new tailored clinical approach. The positive scientific opinion marks a key regulatory milestone for the company's biosimilar pipeline in European markets. The update was formally communicated through an NSE filing on September 21, 2026.
How strong was Biocon Limited.’s trading volume?
1.70 lakh shares traded, 0.06 times the 20-day average daily volume. The price and volume data are dated 14 October 2026 · 09:45 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.